Psoriatic Arthritis Treatment Market Size, Share and Industry Analysis By Drug Class (Non-steroidal Anti-inflammatory Drugs (NSAIDS), Non-biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Others), By Route of Administration (Oral, Parenteral, Topical), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online pharmacies) and Regional Forecast, 2020 – 2029 (Includes COVID-19 Business Impact)

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Psoriatic Arthritis Treatment Market.

Trusted Business Insights presents an updated and Latest Study on Psoriatic Arthritis Treatment Market. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market. The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Psoriatic Arthritis Treatment Market during the forecast period.
It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Psoriatic Arthritis Treatment Market Size, Share and Industry Analysis By Drug Class (Non-steroidal Anti-inflammatory Drugs (NSAIDS), Non-biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Others), By Route of Administration (Oral, Parenteral, Topical), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online pharmacies) and Regional Forecast, 2020 – 2029 (Includes COVID-19 Business Impact)

We have updated Psoriatic Arthritis Treatment Market with respect to COVID-19 Business Impact.
Inquire before buying

This report focuses on the Psoriatic Arthritis Treatment market and value at the global level, regional level, and company level. From a global perspective, this report represents the overall Psoriatic Arthritis Treatment market size by analyzing historical data and future prospects. Regionally, this report focuses on several key regions: North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America.

Global Psoriatic Arthritis Treatment Market: Segment Analysis

The research report includes specific segments by region (country), by Company, by Type, and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2019 to 2029. An in-depth analysis of the segments assists in identifying the different factors that will aid market growth.

Global Psoriatic Arthritis Treatment Market: Regional Analysis

The research report includes a detailed study of regions of North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America. The report has been curated after observing and studying various factors that determine regional growth such as the economic, environmental, social, technological, and political status of the particular region. Researchers have studied the data of revenue, sales, and manufacturers of each mentioned region. This section analyses region-wise revenue and volume for the forecast period of 2019 to 2029.

Global Psoriatic Arthritis Treatment Market: Competitive Landscape

This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2019 to 2029.
List of Companies Profiled

  • AbbVie Inc.
  • Novartis AG
  • Johnson & Johnson Services, Inc.
  • Pfizer Inc.,
  • LEO Pharma A/S
  • Merck & Co., Inc.
  • Amgen Inc.
  • Eli Lilly and Company
  • CELGENE CORPORATION
  • UCB S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Other prominent players

Report Coverage
The report provides qualitative and quantitative insights on psoriatic arthritis treatment industry trends and detailed analysis of market size & growth rate for all possible segments in the market. The market segments include drug class, route of administration, and distribution channel. Based on drug class, the psoriatic arthritis treatment market segments include non-steroidal anti-inflammatory drugs (NSAIDs), non-biologic disease modifying anti-rheumatic drugs (DMARDs), biologic disease modifying anti-rheumatic drugs (DMARDs), and others. In terms of the route of administration, the market is categorized into oral, parenteral, and topical routes of administration. Based on the distribution channel, the global market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Geographically, the market is segmented into five major regions, which are North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The regions are further categorized into countries.
Along with this, the report analysis comprises of psoriatic arthritis treatment market dynamics and competitive landscape. Additionally, the report offers insights on the prevalence of psoriatic arthritis for key countries/region, recent industry developments such as partnerships, mergers & acquisitions, new product launches, etc.; pipeline analysis for key companies, the regulatory framework by key countries, and global reimbursement scenario.

SEGMENTATION

 

By Drug Class

  • Non-steroidal Anti-inflammatory Drugs (NSAIDS)
  • Non-biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs)
  • Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs)
  • Others

By Route of Administration

  • Oral
  • Parenteral
  • Topical

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online pharmacies

By Geography

  • North America (U.S. and Canada)
  • Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
  • Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)
  • Latin America (Brazil, Mexico, and Rest of Latin America)
  • Middle East & Africa (South Africa, GCC and Rest of the Middle East & Africa)

Key Industry Developments

In Aug 2020, LEO Pharma A/S announced the sale of a portfolio of four non-core products to Cheplapharm for EUR 300 million. The agreement represents a milestone in the roll-out of LEO Pharmas 2030 strategy which increases the companys focus on new innovative solutions for medical dermatology.
The divested portfolio comprises four products within bone disorders/nephrology, dermatology and gynecology: One-Alpha©(Alfacalcidol), Locoid©(Cortisol), Pimafucin©(Natamycin), and Zineryt©(Erythromycin 40 mg and Zinc Acetate dihydrate). The annual turnover of the portfolio in 2019 amounted to approximately EUR 110 million.
The transaction is expected to close by December 2020, subject to satisfaction of customary closing conditions, including receipt of regulatory approvals. Following the closing, LEO Pharma and Cheplapharm will work closely together to ensure a smooth and effective transition of the products and business.

In March 2019, AbbVie Inc. announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved SKYRIZI (risankizumab), an interleukin-23 (IL-23) inhibitor, for the treatment of plaque psoriasis, generalized pustular psoriasis, erythrodermic psoriasis and psoriatic arthritis in adult patients who have an inadequate response to conventional therapies.

In October 2018, Novartis AG announced that the European Commission (EC) has approved a label update for Cosentyx (secukinumab).

In December, 2017, Pfizer Inc. announced that USFDA has approved its product Infliximab, a chimeric human-murine monoclonal antibody (mAb) against tumor necrosis factor, as a biosimilar to Remicade as a treatment for patients with rheumatoid arthritis, Crohn”s disease, pediatric Crohns disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis.

In December 2017, Eli Lilly and Company announced that USFDA has approved Taltz (ixekizumab) injection 80 mg/mL for the treatment of adults with active psoriatic arthritis (PsA)

&nbsp

Looking for more? Check out our repository for all available reports on Psoriatic Arthritis Treatment Market in related sectors.

Quick Read Table of Contents of this Report @ Psoriatic Arthritis Treatment Market Size, Share and Industry Analysis By Drug Class (Non-steroidal Anti-inflammatory Drugs (NSAIDS), Non-biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Others), By Route of Administration (Oral, Parenteral, Topical), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online pharmacies) and Regional Forecast, 2020 – 2029 (Includes COVID-19 Business Impact)

Contacts

Trusted Business Insights
Shelly Arnold
Media & Marketing Executive
Email Me For Any Clarifications
Connect on LinkedIn
Click to follow Trusted Business Insights LinkedIn for Market Data and Updates.
US: +1 646 568 9797
UK: +44 330 808 0580